tbuckley/cabot-search huggingface dataset:
Abstract P352: Racial Disparity in Post-stroke Readmission - a South Carolina Perspective
Authors: Pratik Y Chhatbar, Jihad S Obeid, Daniel T Lackland, Suzanne P Burns, Joy N Buie, Wuwei Feng, Gayenell S Magwood, Robert J Adams
Journal: Circulation (2018)

Background: Readmissions after acute hospitalizations are a cause of both risk and expense, and many of them are potentially preventable. Importantly, risk-standardized hospital readmission rates are sometimes used as a yardstick of the quality of care offered. However, racial variability in readmissions might involve factors beyond quality of care and has not been studied extensively. During our pilot investigation using 90-day post-stroke readmissions data at Medical University of South Carolina (MUSC), we found significant disparities between African Americans and Caucasians. Objective: To identify differences in readmissions between African Americans and other races and determine preventable readmissions from a pragmatic viewpoint. Methods: We obtained deidentified data from Health Sciences South Carolina (HSSC) Clinical Data Warehouse (CDW). The data was comprised of three institutions: Medical University of South Carolina (MUSC), Palmetto Health and Greenville Hospital System University Medical Center. The data consisted of on adult admissions with index diagnosis considered as an ischemic stroke (or closely related) using International Classification of Diseases, Ninth and Tenth Revision (ICD-9, ICD-10) codes between January 2011 and April 2017. Of these, we will determine readmission and reason for readmission over 90-day period. Readmission can be hospital or emergency room readmission. Results: Our database contains 32,548 patients who have been provided clinical care for stroke. Out of these patients 8,308 (25.5%), 23,085 (70.9%) and 1,155 (3.5%) are African Americans, Caucasians and others, respectively. We will present weekly readmission trends over 90 days and evaluate if there are disparities across races. We will apply chi-square test and Student’s t-test to determine statistical significance. For weekly readmission trends over 90 days, we will apply Kolmogorov-Smirnov test to identify difference in readmission patterns across races. We will also identify confounders like socioeconomic status and age and their influence in the racial disparity. Conclusions: From a single center retrospective data, we found that 90-days readmission rates involve African Americans in a disproportionate manner. This multicenter data analysis will further shed light on the etiology of readmission, confounders and the care offered.
Abstract 17268: ApoA-I Mimetic Peptide 4F Suppresses the Elevation of Pro-Inflammatory Lipid Mediators in Mouse Models of Inflammatory Bowel Disease
Authors: David Meriwether, Carmen Volpe, Victor Grijalva, Ellen O’Connor, Nasrin Dorreh, Alan M Fogelman, Srinivasa T Reddy
Journal: Circulation (2018)

Introduction: Inflammatory bowel disease (IBD) has been linked to an increased prevalence of early stage vascular disease. ApoA-I mimetic peptides including 4F are potential therapeutic agents for the treatment of inflammatory diseases including atherosclerosis, and their mechanism of action appears localized to the intestine. We have reported that 4F protects against the development of disease in both the piroxicam-accelerated IL10-/- and myeloid COX2-/- mouse models of IBD. Hypothesis: We previously reported that plasma and lesion levels of oxidized products of linoleic and arachidonic acid correlate with disease in mouse models of atherosclerosis, and that 4F protects against disease in these models while inhibiting accumulation of these pro-inflammatory mediators. We thus sought to determine the complete lipid pro-inflammatory mediator profiles of both the COX2- and IL10-dependent models of IBD, while also determining the effect of 4F on the pro-inflammatory lipid profiles. Methods: We developed and validated a LC-ESI-MS/MS method for determining the levels of 40 lipid inflammatory mediators in both intestinal tissue and plasma, and we analyzed the effects of both disease and 4F upon these mediators in both IBD models. We also employed Ussing chambers to investigate ex vivo the direct effect of 4F on the clearance of pro-inflammatory lipid mediators from intestinal explants and serosal-side lipoproteins. Results: Disease in both models correlated with significantly elevated tissue and plasma levels of multiple lipid pro-inflammatory mediators, while the protective effects of 4F correlated with the significant suppression of most of these mediators. Of interest, 4F inhibited the disease dependent increase of 15HETE, 12HETE, 5HETE, 13HODE, LTB4, 6ketoPGF1α, PGF2α, and TXB2 in the COX2-/- model; and 15HETE, 12HETE, 13HODE, LTB4, and LTE4 in the IL10-/- model. Ex vivo, we showed that 4F could directly clear the pro-inflammatory mediators from inflamed intestinal explants, while also mediating their trans-intestinal efflux from serosal-side lipoproteins. Conclusions: 4F appears to protect against IBD in part by inhibiting the accumulation of pro-inflammatory lipid mediators, through a mechanism that involves the intestinal clearance of these mediators from tissue and plasma.
TCT-306 Hemodynamic Assessment Of Low Flow, Low Gradient Severe Aortic Stenosis With Preserved EF Using A Pressure Wire
Authors: Zaher Fanari, Jhapat Thapa, Kamleish Persad, Sumaya Hammami, Michael Kostal, Joseph T. West, Erik S. Marshall, William Weintraub, Andrew Doorey
Journal: Journal of the American College of Cardiology (2015)
The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE)
Authors: Michael Mielewczik, Graham D. Cole, Alexandra N. Nowbar, Richard Schilling, Zachary I. Whinnett, Pierre Bordachar, Peter Wilmshurst, John C. Chambers, Brian Olshansky, John Morgan, Carsten Israel, Amarjit S. Sethi, Marc van Houwelingen, John G. Cleland, Georg Schmidt, Darrel P. Francis
Journal: Journal of the American College of Cardiology (2013)
A collaborative classroom investigation of the evolution of SABATH methyltransferase substrate preference shifts over 120 million years of flowering plant history
Authors: Nicole M Dubs, Breck R Davis, Victor de Brito, Kate C Colebrook, Ian J Tiefel, Madison B Nakayama, Ruiqi Huang, Audrey E Ledvina, Samantha J Hack, Brent Inkelaar, Talline R Martins, Sarah M Aartila, Kelli S Albritton, Sarah Almuhanna, Ryan J Arnoldi, Clara K Austin, Amber C Battle, Gregory R Begeman, Caitlin M Bickings, Jonathon T Bradfield, Eric C Branch, Eric P Conti, Breana Cooley, Nicole M Dotson, Cheyone J Evans, Amber S Fries, Ivan G Gilbert, Weston D Hillier, Pornkamol Huang, Kaitlin W Hyde, Filip Jevtovic, Mark C Johnson, Julie L Keeler, Albert Lam, Kyle M Leach, Jeremy D Livsey, Jonathan T Lo, Kevin R Loney, Nich W Martin, Amber S Mazahem, Aurora N Mokris, Destiny M Nichols, Ruchi Ojha, Nnanna N Okorafor, Joshua R Paris, Thais Fuscaldi Reboucas, Pedro Beretta Sant’Anna, Mathew R Seitz, Nathan R Seymour, Lila K Slaski, Stephen O Stemaly, Benjamin R Ulrich, Emile N Van Meter, Meghan L Young, Todd J Barkman
Journal: Molecular Biology and Evolution (2022)

Next-generation sequencing has resulted in an explosion of available data, much of which remains unstudied in terms of biochemical function; yet, experimental characterization of these sequences has the potential to provide unprecedented insight into the evolution of enzyme activity. One way to make inroads into the experimental study of the voluminous data available is to engage students by integrating teaching and research in a college classroom such that eventually hundreds or thousands of enzymes may be characterized. In this study, we capitalize on this potential to focus on SABATH methyltransferase enzymes that have been shown to methylate the important plant hormone, salicylic acid (SA), to form methyl salicylate. We analyze data from 76 enzymes of flowering plant species in 23 orders and 41 families to investigate how widely conserved substrate preference is for SA methyltransferase orthologs. We find a high degree of conservation of substrate preference for SA over the structurally similar metabolite, benzoic acid, with recent switches that appear to be associated with gene duplication and at least three cases of functional compensation by paralogous enzymes. The presence of Met in active site position 150 is a useful predictor of SA methylation preference in SABATH methyltransferases but enzymes with other residues in the homologous position show the same substrate preference. Although our dense and systematic sampling of SABATH enzymes across angiosperms has revealed novel insights, this is merely the "tip of the iceberg" since thousands of sequences remain uncharacterized in this enzyme family alone.
CHRONIC INVERSION OF THE UTERUS. REDUCTION BY A NEW METHOD.
Authors: HENRY O. MARCY
Journal: JAMA (1889)

It is my purpose in this paper to consider only chronic cases of inversion of the uterus, as they are usually presented to the attention of the gynecologist. Cases of partial inversion occurring at labor are believed to be far more common than the teachings of the text-books would lead us to accept. More than once it has occurred under my own observation, and in a recent discussion upon the subject by the members of the Boston Gynecological Society, a considerable number of cases were reported. It was undoubtedly more frequent during the earlier practice of the midwives, when traction upon the umbilical cord was commonly practiced, in order to bring away the placenta. There is much disagreement of opinion as to the cause of inversion even in these cases, although it is conceded that the uterus is generally very flaccid and muscular contraction of the organ is either irregular
Highlights
Journal: JAMA (2013)

Evidence to support the choice of colloid vs crystalloid solutions for the management of hypovolemic shock remains unclear.In a multinational randomized trial that involved 2857 patients with hypovolemic shock admitted to 57 intensive care units, Annane and colleagues assessed the effect on mortality of fluid resuscitation with colloid vs crystalloid solutions.The authors found that use of colloids compared with crystalloids did not result in a difference in 28-day mortality.In an Editorial, Seymour and Angus discuss fluid resuscitation in critically ill patients.
Abstract 13016: Clinical Outcomes Following Emergent Percutaneous Coronary Intervention for Acute Total/subtotal Occlusion of the Left Main Coronary Artery
Authors: Naoki Shibata, Norio Umemoto, Akihito Tanaka, Kensuke Takagi, Hiroshi Tashiro, Naoki Yoshioka, Kiyokazu Shimizu, Itsuro Morishima, Hideki Ishii, Toyoaki Murohara
Journal: Circulation (2020)

Introduction: Acute coronary syndrome involving the unprotected left main coronary artery (LMCA) is a fatal event. However, data regarding clinical features and outcomes in patients presenting with acute total/subtotal occlusion of the unprotected LMCA remain limited, and the impact of vital status in the emergency room (ER) remains unknown in such subjects. Methods: From a multi-center registry of 11977 emergent percutaneous coronary interventions (PCIs), 134 patients due to acute total/subtotal occlusion of the unprotected LMCA were reviewed. ER status classification was defined according to the presence of cardiogenic shock and cardiopulmonary arrest (CPA) in the ER (class 1=no cardiogenic shock; class 2= cardiogenic shock but not CPA; and class 3=CPA). We evaluated in-hospital mortality and cerebral performance category (CPC) as the endpoints. Results: One-half (67/134) of the enrolled patients presented with total occlusion of the unprotected LMCA. Regarding ER status classification, class 1, 2, and 3 were observed in 30.6%, 45.5%, and 23.9% of the patients, respectively. In-hospital mortality occurred in 73 (54.5%) patients, then of the remaining patients, 52 (85.3%) could be discharged with favorable neurological outcomes (CPC 1 or 2). ER status classification (odds ratio 4.79 [95% confidence interval: 2.39-9.62]; p&lt;0.001) and total occlusion of the unprotected LMCA (odds ratio 5.79 [95% confidence interval 2.27-14.73]; p&lt;0.001) were strong predictors of in-hospital mortality. Conclusions: Acute total/subtotal occlusion involving the unprotected LMCA appeared to be associated with high in-hospital mortality. ER status classification and initial flow in the unprotected LMCA were important predictive factors of in-hospital mortality.
Real-world use of PARP inhibitors in BRCA1/2-mutated pancreatic cancer: A retrospective analysis.
Authors: Suvina Amin, Weiyan Li, Seongjung Joo, Gboyega Adeboyeje, Patricia DeArbeloa, Emanuel Petricoin, Edik Matthew Blais, Michael J. Pishvaian
Journal: Journal of Clinical Oncology (2022)

599 Background: BRCA1 or BRCA2 mutations can be found in approximately 6 to 8 percent of patients patients with metastatic pancreatic adenocarcinoma (mPaC). Olaparib is the only PARP inhibitor (PARPi) approved in the EU and the US as maintenance treatment for biomarker-selected patients with mPaC in the 1st line platinum-sensitive setting. However, treatment sequencing can be heterogeneous, and there is a lack of real-world data on patterns of PARPi use in relation to platinum use in BRCA1/2-mutated mPaC. Methods: Longitudinal records collected between 1/2012-12/2020 were analyzed for a cohort of 55 mPaC patients with BRCA1 or BRCA2 mutations identified by commercial NGS testing who enrolled in Perthera’s US real-world observational registry study. Treatment patterns including PARPi utilization and platinum-sensitivity (16 weeks without progression at any point within known history) were abstracted via physician notes across all lines of therapy. Results: PARPi use was documented in 60% (N=33) of 55 patients with BRCA1/2-mutated mPaC in any treatment setting. Within this cohort, 21 patients received a single agent PARPi outside of clinical trials. Among these patients, only 38% (8 of 21) transitioned to a PARPi in a platinum-sensitive context, and only 14% (3 of 21) of these transitions occurred before 2nd line. Notably, 6 patients received a PARPi in the platinum-resistant setting. Within the broader cohort, platinum-sensitive criteria was fully met for 73% (40 of 55); however, only 49% (27 of 55) reached this milestone of platinum-sensitivity prior to initiating a 2nd line therapy. Conclusions: The majority of these BRCA1/2-mutated patients received a PARPi-based therapy in a variety of contexts with respect to line of therapy and prior platinum history. These findings highlight the value of upfront genetic and molecular testing and the need for further exploration to identify factors associated with treatment response as well as optimized treatment sequencing.
From the National Institutes of Health
Authors: C. Lenfant
Journal: JAMA (1994)

<h3>Speed Urged for Thrombolytic Therapy in Acute Myocardial Infarction</h3> : Treatment of all eligible patients with acute myocardial infarction (AMI) with thrombolytic drugs within 30 minutes of arrival at a hospital should be a goal for all emergency departments, according to the first published recommendations (<i>Ann Emerg Med</i>. 1994;23:311-329) of the National Heart Attack Alert Program (NHAAP) Coordinating Committee. The National Heart, Lung, and Blood Institute (NHLBI) established the committee, which includes representatives from 39 scientific, professional, governmental, and voluntary organizations, to assist the NHAAP in achieving its goal of reducing AMI morbidity and mortality, including AMI-related sudden death. The new report—prepared by an NHAAP working group cochaired by Costas Lambrew, MD, Maine Medical Center, Portland, and Mark Smith, MD, George Washington University Medical Center, Washington, DC—lays out the scientific rationale for this recommendation and proposes specific measures emergency departments should take to minimize time to reperfusion and thus maximize myocardial
CONGENITAL POLYKERATOSIS.
Authors: A. TOURAINE
Journal: British Journal of Dermatology (1954)

Journal Article CONGENITAL POLYKERATOSIS. Get access A. TOURAINE A. TOURAINE Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 66, Issue 8-9, 1 August 1954, Pages 294–299, https://doi.org/10.1111/j.1365-2133.1954.tb12637.x Published: 01 August 1954
ROLE OF SEVERE ACIDEMIA ON NEUROLOGIC OUTCOME OF CARDIAC ARREST SURVIVORS UNDERGOING THERAPEUTIC HYPOTHERMIA
Authors: Nishant Patel, Harsha Vardhan Ganga, Sanjeev Nair, Aswathnarayan Manandhi, Ankur Gupta, B M Pampana Gowd, Justin Lundbye
Journal: Journal of the American College of Cardiology (2013)
Correction:<i>Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19</i>
Authors: Emmanuel Normant, Ammar Adam, Marisa O Peluso, Caroline M Armet, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson
Journal: Journal for ImmunoTherapy of Cancer (2020)

In the main text, ► The sentence 'The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 SARS-COV-2 virus…' now reads 'The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus…' ► The sentence 'One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma)…' now reads 'One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra TM , Roche-Genentech), sarilumab (Kevzara TM , Regeneron) and siltuximab (Sylvant TM , EUSA Pharma)…' ► The sentence '…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized COVID-19-infected patients during this extraordinary situation' now reads '…including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized SARS-CoV-2-infected patients during this extraordinary situation' 4) To acknowledge medical writing support, the acknowledgment section has been updated to read:'The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic.
The Flutter of the Goldleaf, and Other Plays.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of difamilast ointment on atopic dermatitis in Japanese children
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Saeki et al. Br J Dermatol 2022; 186:40–49. Atopic dermatitis (AD also known as ‘eczema’) is a chronic skin disease that mainly causes itch and blistering. It is most common in children and has many negative consequences. Topical therapies (that are applied to the skin) are the main treatment for AD but are limited. New safe and effective treatments are therefore needed. One new treatment, difamilast, acts on an important part of the inflammation that causes AD. In this trial, we aimed to find out if difamilast ointment was better than a non-active ointment base (‘vehicle’) for improving AD rash in Japanese children aged 2 to 14 years old. We randomly divided 251 children with mild-to-moderate AD to receive either difamilast (at strengths of 0·3% or 1%) or the vehicle twice a day, applied to affected areas. We then used a well-known score to assess the success of each ointment at improving the rash after 1, 2 and 4 weeks of treatment. After 4 weeks of treatment, we found that 45–47% of children who received either difamilast 0·3% or difamilast 1% ointment had been successfully treated according to the scoring criteria, compared with 18% of children who received the vehicle ointment. Difamilast treatment also improved troublesome symptoms, especially itch, to a greater extent than vehicle and often as early as 1 week after treatment started. Children treated with difamilast had few side-effects and left the trial less often than children treated with the vehicle. In conclusion, this trial shows that difamilast is effective at treating AD in Japanese children and was well tolerated. Linked Article: Saeki et al. Br J Dermatol 2022; 186:40–49.
Errors in Figure Captions
Journal: JAMA Network Open (2021)

Zongming Gao, PhD; Michael Karfunkle, MS; Wei Ye, MS; Tim Andres Marzan, MS; Jingyue Yang, PhD; Timothy Lex, PhD; Cynthia Sommers, MS; Jason D. Rodriguez, PhD; Xiaomei Han, MD; Jeffry Florian, PhD; David G. Strauss, MD, PhD; David A. Keire, PhD
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Authors: T. André, A. Falcone, Y. Shparyk, F.V. Moiseenko, E. Polo Marques, T. Csoszi, A. Campos Bragagnoli, G. Liposits, E. Chmielowska, P. Aubel, L. Martín-Fernández, R. Fougeray, N. Causse-Amellal, M.P. Saunders
Journal: Annals of Oncology (2021)
Reporting Both Unadjusted and Adjusted Estimates Is Essential to the Interpretation of Randomized Clinical Trial Results
Authors: Robert S. Ware
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Multielectrode basket catheter-guided ablation for pulmonary venous isolation in atrial fibrillation Koichiro Kumagai, Naomichi Matsumoto, Hideaki Tojo, Hiroo Noguchi, Hideko Nakashima, Naoki Gondo, Keijiro Saku. Fukuoka University Hospital, Fukuoka, Japan
Journal: Journal of the American College of Cardiology (2001)